Sign in

    Andrew Ranieri

    Vice President in Medical Technology Equity Research at Morgan Stanley

    Andrew (Drew) Ranieri is a Vice President in Medical Technology Equity Research at Morgan Stanley, specializing in in-depth analysis of the medical technology sector. He provides coverage on key companies within the medical devices and healthcare technology space, where his research contributes to investment decisions by both institutional and retail investors. Ranieri began his equity research career prior to joining Morgan Stanley and has demonstrated a strong analytical track record, assisting clients in identifying high-potential opportunities in medtech—though explicit rankings or performance metrics are not publicly specified. He is known for his expertise in the field and holds relevant professional credentials for equity research roles in the financial industry.

    Andrew Ranieri's questions to SI-BONE (SIBN) leadership

    Andrew Ranieri's questions to SI-BONE (SIBN) leadership • Q3 2024

    Question

    Andrew Ranieri from Morgan Stanley asked about the drivers behind the 25% year-over-year volume growth from same surgeons and what is needed to accelerate this adoption further in 2025. He also questioned the dynamics behind the 3% ASP increase and the outlook for Q4.

    Answer

    CEO Laura Francis attributed the growth to a 35% increase in physicians performing multiple procedure types across the company's platform. CFO Anshul Maheshwari added that the 25% growth from seasoned surgeons is a key positive indicator for future productivity. Regarding the ASP increase, Maheshwari explained it was driven by a favorable product mix, specifically a 40% increase in 'stacked' Granite cases using four implants, rather than price increases.

    Ask Fintool Equity Research AI

    Andrew Ranieri's questions to Alphatec Holdings (ATEC) leadership

    Andrew Ranieri's questions to Alphatec Holdings (ATEC) leadership • Q3 2024

    Question

    Andrew Ranieri asked for more context on how EOS orders create a foundation for implant growth and questioned the drivers behind the weaker-than-expected gross margin.

    Answer

    Executive Patrick Miles explained that the EOS surgical planning element is informed by and integrated with ATEC's implants, creating a proprietary, end-to-end solution that ties the implants directly to the plan. Executive J. Koning attributed the gross margin softness to product mix, specifically lower margins on international EOS sales and a strong quarter for lower-margin biologics. He guided for a Q4 non-GAAP gross margin around 69.5%.

    Ask Fintool Equity Research AI